PMV Pharmaceuticals, Inc. — Q3 2020 Form 10-Q
Business context and period: Unaudited results for the quarter and nine months ended September 30, 2020; balance-sheet comparisons are with December 31, 2019. PMV is a preclinical precision-oncology company developing small-molecule therapies targeting p53 mutations. It had no approved products, no product revenue, and no product candidates in clinical trials at quarter-end. The filing reports FDA authorization to proceed under an IND for lead candidate PC14586 in September; the company later reported fast track designation in October 2020.
Financial results and liquidity
- Revenue: None; the company does not expect product revenue in the foreseeable future.
- Q3 2020: R&D expense was $6.0 million, G&A expense $2.7 million, and total operating expenses $8.7 million. Net loss was $8.8 million, versus $6.2 million in Q3 2019. Basic and diluted net loss per share was $1.46, compared with $2.03.
- Nine months: Operating expenses were $24.4 million, including R&D of $17.8 million and G&A of $6.7 million. Net loss was $24.0 million, versus $18.3 million in the prior-year period; loss per share was $5.93 versus $6.04.
- Cash flow: Nine-month cash used in operations was $22.4 million, compared with $16.9 million in 2019. Investing activities provided $28.0 million, largely from maturities of marketable securities. Financing provided $294.3 million, principally from the IPO and Series D preferred-stock issuance. Cash and cash equivalents increased by $299.9 million.
- Balance sheet at September 30: Cash and cash equivalents were $373.2 million; short-term marketable securities were zero. Current liabilities were $5.5 million, total liabilities $5.5 million, and stockholders’ equity $369.0 million. The filing reports no debt.
- Margins: Not meaningful because the company had no revenue. Interest income, net, was $0.04 million for Q3 and $0.6 million for the nine months.
Material changes versus comparable periods
- Q3 operating expenses increased $2.3 million year over year. R&D rose $1.1 million, mainly from personnel and stock-based compensation, including increased PC14586 development and Y220C IND-enabling work. G&A rose $1.2 million, primarily from staffing, professional services, and investor-relations costs.
- Nine-month operating expenses increased $5.2 million. Higher preclinical-development and personnel costs were partly offset by lower research costs. Net loss increased $5.7 million.
- In July, PMV raised $70.0 million gross through Series D preferred stock. Its September IPO raised $243.5 million gross and $223.2 million net. Preferred stock converted into common stock at the IPO; common shares outstanding were 44,773,748 at September 30.
- Cash and cash equivalents rose from $73.3 million at year-end 2019 to $373.2 million at September 30, 2020, primarily reflecting equity financing and investment maturities.
Outlook, risks, and other notable items
- Management expects substantial additional operating losses and higher R&D spending as programs advance. It states in the financial-statement note that available cash should fund operations for at least 12 months from issuance; elsewhere in risk disclosures, it says available resources are expected to fund planned operations through 2023. These are different runway statements and should be reconciled.
- Funding needs depend on development timelines, trial scope, regulatory requirements, manufacturing, hiring, and other factors. Future equity financing could dilute shareholders; debt or partnering could impose restrictions or require surrendering rights.
- Key risks include the early, unproven stage of the p53-targeting approach; dependence on PC14586; clinical, regulatory, patient-enrollment and companion-diagnostic uncertainties; reliance on CROs and contract manufacturers, including suppliers in China; intellectual-property protection; competition; and COVID-19 disruption to research, trials, supply chains, and markets.
- PMV reported no material litigation and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of September 30, 2020, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Reconcile the stated cash runway through 2023 with the separate statement that cash covers at least 12 months from financial-statement issuance; assess assumptions behind both estimates.
- Verify PC14586’s IND status, planned first-in-human Phase 1/2 trial timing, and the scope and conditions of its October 2020 fast track designation.
- Track cash burn and planned increases in R&D and public-company costs against the $373.2 million cash balance; confirm whether additional capital or collaboration funding becomes necessary.
- Monitor clinical and preclinical evidence, enrollment feasibility for mutation-specific populations, companion-diagnostic development, and third-party manufacturing and supply risks.
- Assess potential dilution and trading overhang: the filing describes lock-up expirations and registration rights affecting substantial numbers of shares, alongside equity-plan reserves.